Published Date: 08 Mar 2023
A new review article titled "Cellular Aging: When Growth Stimuli Meet Cell Cycle Arrest" is published in Aging.
Read Full NewsScreening for insulin resistance early after the diagnosis of hidradenitis suppurativa shows promise for guiding therapies to improve the disease course.
At 52 weeks, the 30-mg daily oral dose of brepocitinib outperformed the 15-mg dose in a study of patients with dermatomyositis resistant to previous treatments.
Combination therapies remain key as multiple agents for melasma hit the market.
CHAMPION-AF finds left atrial appendage closure and anticoagulation therapy for atrial fibrillation about equal but raises doubts about whether the former is a true alternative.
For intermediate-risk pulmonary embolism, a low-dose fibrinolysis strategy reduced PE-related events by half with no significant increase in bleeding vs standard therapy.
A subgroup analysis of the VESALIUS-CV trial showed evolocumab significantly cut LDL cholesterol and cardiovascular event risk in people with diabetes but no known atherosclerosis.
Performed with favorable safety, the diagnostic yield for coronary function testing in patients with ischemia but nonobstructive arteries was found to exceed 90%.
1.
No increased risk of childhood cancer near UK nuclear sites, study finds
2.
It Is Cancer in Kate Middleton.
3.
Belzutifan Combo Could be Second-Line Option in Advanced RCC
4.
Future of Lab-Developed Tests Still Taking Shape
5.
Biomarker panel offers hope for early pancreatic cancer detection
1.
Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide
2.
Revolutionizing Cancer Care: The Transformative Role of AI and Data Science in Oncology
3.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
4.
Personalized Neoantigen Vaccines and the Promise of a Less Toxic Future in Pediatric Oncology
5.
Precision Oncology: Tailoring Cancer Treatment for the Individual
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Breaking Down PALOMA-2: How CDK4/6 Inhibitors Redefined Treatment for HR+/HER2- Metastatic Breast Cancer
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Further Discussion on A New Perspective
5.
A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation